Revision history of "Phase II clinical trial of CELYVIR in combination with chemotherapy for children and adolescents with refractory or relapsed solid tumors" (Q3195981)

Jump to navigation Jump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

7 March 2024

20 December 2023

12 June 2023

10 June 2023

18 August 2022

  • curprev 08:4208:42, 18 August 2022DG Regio talk contribs 64,891 bytes +43,753 Changed label, description and/or aliases in el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl, nl, fr, de, it, es, and other parts: Adding translations: el, da, fi, mt, lv, sk, ga, cs, pt, et, hu, bg, lt, hr, sv, ro, sl, pl,

16 January 2022

17 December 2021

9 December 2021

4 December 2021

12 October 2021

  • curprev 21:5421:54, 12 October 2021DG Regio talk contribs 11,955 bytes +197 Changed label, description and/or aliases in en: translated_label
  • curprev 21:5421:54, 12 October 2021DG Regio talk contribs 11,758 bytes +1,964 Created claim: summary (P836): Childhood cancer, despite being considered a “rare disease”, is the first cause of death due to disease, in Spain, until the age of 14, so there is an unmet need to develop new therapeutic strategies especially in solid tumors in relapse or refractory. Our Oncohematology unit of HUNJ, in collaboration with Dr. García Castro’s group at ISCIII, has accumulated a lot of experience in therapeutic applications of oncolytic adenoviruses. Especially in...

11 October 2021

10 October 2021

8 October 2021